A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal Canal

Inclusion Criteria: * Must have cancer of the anal canal OR rectal cancer. * Must have metastatic disease or persistent/recurrent loco-regional disease * Prior Therapy: may have received \<2 regimens for disease in the metastatic setting. At least one line of therapy. * Be willing and able to provide written informed consent for the trial. * Be ≥18 years of age on day of signing informed consent. * Have measurable disease based on response evaluation criteria in solid tumors (RECIST) 1.1 * Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Demonstrate adequate organ function as defined in protocol. * Females cannot be pregnant or breastfeeding and must take two methods of birth control Exclusion Criteria: * Has not recovered (for example, Grade ≤1 or at baseline) from adverse events (AEs), with the exception of alopecia or Grade ≤2 neuropathy, due to a previously administered agent * Has a diagnosis of immunodeficiency * Has known additional malignancy that is progressing or requires active treatment. Treatment of an additional malignancy with chemotherapy, immunotherapy, biologic or hormonal therapy must have occurred 2 years prior. Concurrent use of hormones for non-cancer-related conditions (for example, insulin for diabetes and hormone replacement therapy) is acceptable * Note: Local treatment of isolated lesions for palliative intent (for example, by local surgery or radiotherapy), basal cell carcinoma of the skin, or squamous cell carci…